The Myeloablative Drug Busulfan Converts Cysteine to Dehydroalanine and Lanthionine in Redoxins
Author:
Affiliation:
1. Department of Medicinal Chemistry, University of Washington, Box 357610, Seattle, Washington 98195-7610, United States
2. Department of Chemistry and Biochemistry, University of South Carolina, Columbia, South Carolina 29208, United States
Funder
National Cancer Institute
National Institute of General Medical Sciences
Department of Medicinal Chemistry, University of Washington
Publisher
American Chemical Society (ACS)
Subject
Biochemistry
Link
https://pubs.acs.org/doi/pdf/10.1021/acs.biochem.6b00622
Reference32 articles.
1. Busulfan in hematopoietic stem cell transplant setting
2. Efficacy and Safety of Busulfan-Based Conditioning Regimens for Multiple Myeloma
3. Busulfan-cyclophosphamide versus total body irradiation–cyclophosphamide as preparative regimen before allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia: What have we learned?
4. Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients
5. Hepatic Venoocclusive Disease in Blood and Bone Marrow Transplantation in Children and Young Adults: Incidence, Risk Factors, and Outcome in a Cohort of 241 Patients
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The presence of busulfan metabolites and pharmacometabolomics in plasma drawn immediately before allograft infusion in hematopoietic cell transplant recipients;Clinical and Translational Science;2023-10-10
2. Population Pharmacokinetic Model of Intravenous Busulfan in Hematopoietic Cell Transplantation: Systematic Review and Comparative Simulations;Clinical Pharmacokinetics;2023-07
3. Characterization and quantitation of busulfan DNA adducts in the blood of patients receiving busulfan therapy;Molecular Therapy - Oncolytics;2023-03
4. Individualizing busulfan dose in specific populations and evaluating the risk of pharmacokinetic drug-drug interactions;Expert Opinion on Drug Metabolism & Toxicology;2023-02-01
5. Population pharmacokinetic model for once‐daily intravenous busulfan in pediatric subjects describing time‐associated clearance;CPT: Pharmacometrics & Systems Pharmacology;2022-06-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3